Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies
NCT03611686 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 219
Last updated 2025-03-24
Summary
Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration
Conditions
- Metastatic Prostate Adenocarcinoma
Interventions
- DRUG
-
Local chemotherapy
Local chemotherapy will be administrated according to local recommendation
Sponsors & Collaborators
-
University Hospital, Rouen
lead OTHER
Principal Investigators
-
Christian PFISTER · University Hospital, Rouen
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-17
- Primary Completion
- 2026-04-30
- Completion
- 2026-04-30
Countries
- France
Study Locations
More Related Trials
-
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation As a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
NCT03655886 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on Drug-drug Interactions in Patients Treated With Anticancer Agents for a Prostate Cancer in Real Life Setting
NCT05612841 ·Status: UNKNOWN
-
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
NCT02066961 ·Status: COMPLETED
-
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
NCT01558427 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
NCT01076751 ·Status: TERMINATED
-
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms
NCT03763253 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
NCT00104715 ·Status: COMPLETED ·Phase: PHASE3
-
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
NCT02236637 ·Status: COMPLETED
-
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
NCT03314324 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
NCT06046131 ·Status: RECRUITING ·Phase: NA
-
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
NCT01254513 ·Status: COMPLETED ·Phase: PHASE2
-
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
NCT03658486 ·Status: COMPLETED ·Phase: NA
-
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
NCT05169112 ·Status: RECRUITING ·Phase: PHASE3
-
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
NCT01858441 ·Status: COMPLETED ·Phase: NA
-
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02008058 ·Status: COMPLETED
-
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
NCT00183924 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
NCT02907372 ·Status: COMPLETED ·Phase: NA
-
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
NCT02485691 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252 ·Status: WITHDRAWN
-
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05973149 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
NCT03902951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer
NCT04220398 ·Status: UNKNOWN ·Phase: NA
-
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
NCT00116142 ·Status: COMPLETED ·Phase: PHASE3
-
Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer
NCT03088124 ·Status: COMPLETED ·Phase: PHASE2